

Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia: results from two clinical trials

Patients with acute myeloid leukemia (AML), who are refractory to induction therapy or experience relapse after a first complete remission (CR), have an unfavorable prognosis.¹ Epigenetic dysregulation is frequent in AML. In preclinical studies, the pan-deacetylase inhibitor (DACi) panobinostat² was shown to modulate the activity of multiple genes in leukemic cell lines,³ demonstrated single agent activity in AML cell lines and potentiated the activity of doxorubicin in preclinical assays.⁴ As a single agent, panobinostat showed modest anti-leukemic activity in early phase clinical trials in advanced hematological malignancies.^{5,6} In patients with myeloid disorders, 60 mg of panobinostat three times per week (TIW) as a single agent in weekly and biweekly schedules was defined as the maximum tolerated dose (MTD).

Based on this limited experience, we performed two clinical trials to evaluate the tolerability and clinical efficacy of panobinostat when given either as oral monotherapy at the previously established MTD, or in combination with intensive chemotherapy for relapsed or refractory (r/r) AML. Panobinostat monotherapy with 60 mg TIW for 28 days (one cycle) was evaluated in a phase II clinical trial following Simon's optimal two-stage design in two strata: A) patients with *de novo* AML, and B) patients with secondary AML. The second study was a phase I study addressing whether panobinostat could be safely combined with Ara-C and mitoxantrone in r/r-

AML in escalating doses in adult patients (age \geq 18 years) with r/r AML. In the dose escalation step, oral doses of panobinostat (20 mg, 30 mg, 40 mg, 50 mg, and 60 mg, TIW) were given with fixed dose Ara-C (0.5 g/m² intravenously (IV) twice daily, days 1-6) and mitoxantrone (5 mg/m² IV, days 1-5) for three 28-day cycles. Patients with CR or complete remission with incomplete blood count recovery (CRi) were eligible for maintenance therapy with oral single agent panobinostat at 60 mg TIW. An adaptive Bayesian logistic regression model for combination therapy, including the escalation with overdose control principle, was used to guide the dose escalation of panobinostat.⁷ The MTD was determined by dose limiting toxicities (DLTs) in patients who had taken sufficient study drug (at least five doses of panobinostat in cycle 1) and had sufficient safety evaluations or discontinued due to dose-limiting toxicity (DLT) in cycle 1. Adverse events (AEs) were evaluated throughout both studies according to the common terminology criteria for adverse events (CTCAE), version 3.0.⁸ Response was evaluated according to Cheson's criteria,⁹ based on investigator's assessment of response.

In the monotherapy study 59 patients with a median age of 66 years (range: 27-84) were enrolled, 32 in Stratum A and 27 in Stratum B. Baseline characteristics are shown in Table 1 (A: monotherapy study; B: combination therapy study). All patients discontinued the study (Table 2), primarily for disease progression (24, 40.7%), AEs (19, 32.2%) and death (6, 10.2%). Fifteen patients (25.4%) entered post-treatment evaluation after six cycles of therapy and continued to be followed after treatment ended. Overall, 43 patients (72.9%) were

Table 1A. Baseline patient demographics and disease characteristics for all patients enrolled in panobinostat monotherapy trial.

Demographic variable n (%)	Monotherapy Trial		
	Stratum A (n=32)	Panobinostat Dose =60 mg Stratum B (n=27)	Total (N = 59)
Sex - Male	12 (37.5)	19 (70.4)	31 (52.5)
Age (years)			
Median (range)	63 (27-83)	68 (49-84)	66 (27-84)
Age Category			
<65 years	18 (56.3)	8 (29.6)	26 (44.1)
\geq 65 years	14 (43.8)	19 (70.4)	33 (55.9)
ECOG PS			
PS = 0	11 (34.4)	5 (18.5)	16 (27.1)
PS = 1	14 (43.8)	17 (63.0)	31 (52.5)
PS = 2	7 (21.9)	5 (18.5)	12 (20.3)
		Disease Status	
<i>De novo</i> AML	32 (100)	0	32 (54.2)
Secondary to MDS	0	23 (85.2)	23 (39.0)
Secondary to AHD	0	4 (14.8)	4 (6.8)
Refractory to initial induction	13 (40.6)	15 (55.6)	28 (47.5)
Relapsed	18 (56.3)	12 (44.4)	30 (50.8)
		Duration of Initial Response	
\leq 6 months	11 (34.4)	10 (37.0)	21 (35.6)
> 6 to \leq 12 months	10 (31.3)	5 (18.5)	15 (25.4)
> 12 months	11 (34.4)	12 (44.4)	23 (39.0)

Stratum A: refractory *de novo* AML. Stratum B: refractory AML secondary to MDS/AHD. ECOG PS: Eastern cooperative oncology group, performance status; AML: acute myeloid leukemia; MDS: myelodysplastic syndrome; AHD: antecedent hematopoietic disorder.

Table 2. Patient disposition for the monotherapy and combination trials: primary reasons for end of treatment.

Patient Disposition	Monotherapy Trial			Combination Trial					
	Panobinostat Dose 60 mg/d TIW			Panobinostat doses					
	Stratum A (n=32)	Stratum B (n=27)	Total (N=59)	20 mg (n=5)	30 mg (n=8)	40 mg (n=10)	50 mg (n=30)	60 mg (n=6)	Total N=59
Enrolled (treated)	32 (100)	27 (100)	59 (100)	5 (100)	8 (100)	10 (100)	30 (100)	6 (100)	59 (100)
Discontinued	32 (100)	27 (100)	59 (100)	5 (100)	8 (100)	10 (100)	30 (100)	6 (100)	59 (100)
	Primary reason for end of treatment			Primary reason for end of treatment					
treatment									
Completed per protocol				0	2 (25.0)	4 (40.0)	17 (56.7)	3 (50.0)	26 (44.1)
Death	4 (12.5)	2 (7.4)	6 (10.2)	0	1 (12.5)	2 (20.0)	7* (23.3)	1 (16.7)	11 (18.6)
Adverse event(s)	10 (31.3)	9 (33.3)	19 (32.2)	1 (20.0)	1 (12.5)	2 (20.0)	2 (6.7)	2 (33.3)	8 (13.6)
Disease progression	13 (40.6)	11 (40.7)	24 (40.7)	3 (60.0)	0	1 (10.0)	3 (10.0)	0	7 (11.9)
Withdrew consent	3 (9.4)	4 (14.6)	7 (11.9)	0	2 (25.0)	1 (10.0)	0	0	3 (5.1)
Other reasons†	2 (6.3)	1 (3.7)	3 (5.1)	1 (20.0)	2 (25.5)	0	1 (3.3)	0	4 (6.7)
	Entered post-treatment evaluation			Entered extension part of the study					
	10 (31.1)	5 (18.5)	15 (25.4)	1 (20.0)	1 (12.5)	2 (20.0)	0	0	4 (6.8)
	Proceeded to stem cell transplant								
	Unknown		0	2 (25.0)	1 (10.0)	4 (13.3)	0	7 (11.9)	

*One patient stopped treatment due to AEs, but died of disease progression a few days after the end of treatment. This patient is counted as a part of total deaths during the combination trial. †For the single agent trial, other reasons for end of treatment include: lost to follow-up, protocol deviation, and new cancer therapy. For the combination trial, other reasons for end of treatment include: administrative issues, and abnormal test procedure results. TIW: three times per week.

Table 3. Best overall response as per investigator assessment for the combination trial, by initial dose group of panobinostat.

Best overall response	Panobinostat doses					
	20 mg N = 5	30 mg N = 8	40 mg N = 10	50 mg N = 30	60 mg N = 6	Total N = 59
Complete remission (CR)	2 (40.0)	1 (12.5)	5 (50.0)	6 (20.0)	4 (66.7)	18 (30.5)
Morphologic CR with incomplete blood count recovery (CRi)	0	1 (12.5)	0	7 (23.3)	1 (16.7)	9 (15.3)
Partial remission (PR)	0	3 (37.5)	1 (10.0)	2 (6.7)	0	6 (10.2)
Treatment failure	3 (60.0)	2 (25.0)	1 (10.0)	9 (30.0)	0	15 (25.4)
Unknown	0	1 (12.5)	3 (30.0)	6 (20.0)	1 (16.7)	11 (18.6)
Rate of CR or CRi or PR	2 (40.0)	5 (62.5)	6 (60.0)	15 (50.0)	5 (83.3)	33 (55.9)
95% confidence interval (CI)	5.3, 85.3	24.5, 91.5	26.2, 87.8	31.3, 68.7	35.9, 99.6	42.4, 68.8
Time to remission (days)	114 (22, 114)	32.5 (21, 99)	25 (22, 54)	42 (25, 88)	43 (23, 126)	42 (25, 54)
Median (95% CI)						

of study treatment, and three patients in the 50 mg (n=2) and 60 mg (n=1) cohorts received three cycles. Of the 59 patients enrolled, 34 were evaluable for MTD determination. A total of 14 DLTs were observed in six patients; none in the 20 mg and 30 mg dose groups, one in the 40 mg group (grade 4 sepsis and grade 3 tachycardia), two in the 50 mg group (grade 3 diarrhea, grade 3 corrected QT interval derived from Fridericia's formula (QTcF) prolongation, grade 3 nausea, grade 3 toxic exanthema, grade 3 vomiting) and three in the 60 mg group (grade 4 sepsis, grade 3 neutropenic colitis, grade 3 worsening bilateral pneumonia, grade 3 diarrhea leading to hypokalemia, grade 3 pancytopenia, grade 3 hypokalemia). The MTD was determined to be 50 mg panobinostat in the study dosing schedule. The chance of either excessive or unacceptable toxicity at this MTD dose was calculated to be 5.9% (i.e., < 25%), while for 60 mg panobinostat, this was calculated to be 34.4% (i.e., ≥ 25%). All 59 patients treated with panobinostat combination therapy experi-

enced at least one AE that was suspected to be related to study treatment in 93% of patients, and in 88% of the patients this was a grade ≥ 3 AE. The most common grade ≥ 3 non-hematologic AEs suspected to be related to the study treatment were diarrhea (20%), nausea (5%), vomiting (5%), hypokalemia (7%), and sepsis (5%). AEs led to study discontinuation in 19 patients (32%), and in 6 (10%) of these patients discontinuation was due to an SAE considered to be related to the study treatment. The most frequent AEs leading to discontinuation were sepsis, including septic shock and fungal sepsis (seven events), QT prolongation and hypokalemia (two events each). Eleven patients (19%) died during or within 28 days of completing treatment. The causes of deaths were sepsis (n=5), septic shock (n=2), fungal infection (n=1), candidiasis (n=1), acute respiratory distress syndrome (n=1) and intracranial hemorrhage (n=1). By investigator assessment, the overall response rate with the combination therapy was 56% (CR in 18 patients [31%], CRi in 9

patients [15%], and partial response (PR) in 6 patients [10%]. The response rate at the MTD (50 mg) was 50%, (CR, 20% plus CRi, 23% plus PR, 7%). Responses were seen at all dose levels of panobinostat without clear evidence of the dose response relationship (Table 3). Responses were seen exclusively in patients with the European LeukemiaNet (ELN) 2010 favorable- or intermediate-1 risk group as well as in patients with a first CR > 6 months. Taken together at the previously reported MTD dose of 60mg for single agent therapy, panobinostat was efficacious only in single cases and was poorly tolerated in patients with r/r-AML. Other DACi's, such as vorinostat,¹⁰ belinostat,¹¹ and entinostat¹² also showed poor efficacy in AML when used as a single agent. The MTD of panobinostat in combination with mitoxantrone and cytarabine was found to be 50 mg thrice weekly, which was comparable to the MTD of 60 mg determined for single agent panobinostat. The addition of panobinostat did not significantly increase the rate of AEs. In two other studies¹³ evaluating panobinostat in combination with idarubicin and cytarabine within a standard 7+3 induction therapy the identified MTD was considerably lower (10mg and 20mg, respectively), suggesting a relevant drug-drug interaction between panobinostat and idarubicin that is not relevant in combination with mitoxantrone. A CR/CRi rate in the combination therapy study of 46% and an overall survival rate of 15% at four years do not indicate promising efficacy.¹

Richard F. Schlenk,^{1,2} Jürgen Krauter,³ Emmanuel Raffoux,⁴ Karl-Anton Kreuzer,⁵ Markus Schaich,⁶ Lucien Noens,⁷ Thomas Pabst,⁸ Madhuri Vusirikala,⁹ Didier Bouscary,¹⁰ Andrew Spencer,¹¹ Anna Candoni,¹² Jorge Sierra Gil,¹³ Noah Berkowitz,¹⁴ Hans-Jochen Weber¹⁵ and Oliver Ottmann¹⁶

¹NCT Trial Center, National Center for Tumor Diseases Heidelberg, Germany; ²University Hospital Ulm, Department of Internal Medicine III, Germany; ³Department of Hematology, Hemostaseology, Oncology and Stem Cell Transplantation, Hannover Medical School, Germany (Present Address: Department Hematology and Oncology, Braunschweig Municipal Hospital, Germany); ⁴Hôpital Saint-Louis – Service d'Hématologie Adulte, Paris, France; ⁵Department of Internal Medicine I, University of Cologne, Germany; ⁶University of Dresden, Department of Internal Medicine I, Germany (Present Address: Hämatologie, Onkologie und Palliativmedizin, Rems-Murr-Kliniken, Winnenden, Germany); ⁷Universitair Ziekenhuis, Gent, Belgium; ⁸Inselspital, Bern, Switzerland; ⁹University of Texas Southwestern Medical Center, Dallas, TX, USA; ¹⁰Hôpital Cochin, Paris, France; ¹¹The Alfred Hospital, Melbourne, VIC, Australia; ¹²Azienda Ospedaliero-Universitaria "Santa Maria della Misericordia" di Udine, Italy; ¹³Hospital de la Santa Creu i Sant Pau, IIB Sant Pau and Jose Carreras Research Institutes, Barcelona, Spain; ¹⁴Novartis Pharmaceutical Corporation, East Hanover, NJ, USA; ¹⁵Novartis Pharma AG, Basel, Switzerland and ¹⁶University of Frankfurt, Department of Internal Medicine II, Germany (Present Address: Haematology, Division of Cancer and Genetics, Cardiff University, UK)

Funding: The studies were sponsored by Novartis AG, Basel and editorial support was provided by Sujata Swaminathan, Anamika Gulati, and Vinay Kumar Ranka (Scientific Service Practices, Novartis Healthcare Private Limited, Hyderabad, India).

Correspondence: richard.schlenk@nct-heidelberg.de
doi:10.3324/haematol.2017.172411

Information on authorship, contributions, and financial & other disclosures was provided by the authors and is available with the online version of this article at www.haematologica.org.

References

- Schlenk RF, Müller-Tidow C, Benner A, Kieser M. Relapsed/refractory acute myeloid leukemia, any progress? *Curr Opin Oncol.* 2017; 29(6):467-473.
- Morabito F, Voso MT, Hohaus S, et al. Panobinostat for the treatment of acute myelogenous leukemia. *Expert Opin Investig Drugs.* 2016;25(9):1117-1131.
- Liu HB, Urbanavicius D, Tan P, Spencer A, Dear AE. Mechanisms and potential molecular markers of early response to combination epigenetic therapy in patients with myeloid malignancies. *Int J Oncol.* 2014;45(4):1742-1748.
- Maiso P, Colado E, Ocio EM, et al. The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair. *Leukemia.* 2009;23(12):2265-2274.
- DeAngelo DJ, Spencer A, Bhalla KN, et al. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. *Leukemia.* 2013;27(8):1628-1636.
- Giles F, Fischer T, Cortes J, et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. *Clin Cancer Res.* 2006;12(15):4628-4635.
- Babb J, Rogatko A, Zacks S. Cancer phase I clinical trials: efficient dose escalation with overdose control. *Stat Med.* 1998;17(10):1103-1120.
- Trotti A, Colevas AD, Setzer A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. *Semin Radiat Oncol.* 2003;13(3):176-181.
- Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. *J Clin Oncol.* 2003;21(24):4642-4649.
- Schaefer EW, Loaiza-Bonilla A, Juckett M, et al. A phase 2 study of vorinostat in acute myeloid leukemia. *Haematologica.* 2009; 94(10):1375-1382.
- Kirschbaum MH, Foon KA, Frankel P, et al. A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study. *Leuk Lymphoma.* 2014;55(10):2301-2304.
- Prebet T, Sun Z, Ketterling RP, et al. Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. *Br J Haematol.* 2016;172(3):384-391.
- DeAngelo DJ, Walker AR, Schlenk RF, et al. A phase 1b study of panobinostat in combination with idarubicin and ara-C in patients with high-risk acute myeloid leukemia. *Blood.* 2015;126(23):2553-2553.